Granted Patent B2

US 8,318,706 · App. 11/963,540 · Granted Nov 27, 2012

Abstract

Claims (24)

1. A compound of formula I:

wherein

X is CR 6′ R 6 , or C═CR 6′ R 6 ;

E is NR 7d R 7e or OR 7f ;

R 2 , R 2′ , R 4′ , R 4a and R 4b are each independently hydrogen, or alkyl;

R 3 , R 10 , R 11 and R 12 are each hydrogen;

R 4 is NR 4a R 4b ;

R 5 and R 5′ are each independently hydroxyl, hydrogen or alkyl;

R 6 and R 6′ are each independently hydrogen, hydroxyl, or alkyl;

R 7a , R 7b , R 7c , R 7d , R 7e and R 7f are each independently hydrogen, alkyl, alkenyl, aryl, or arylalkyl, or R 7c and R 7d or R 7e and R 7f are linked to form a ring;

R 8 is hydrogen; and

R 9 is hydrogen, alkyl, alkenyl, alkynyl, aryl, alkoxy, amino, or aminoalkyl,

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein X is CR 6′ R 6 , R 4a and R 4b are each alkyl, and R 2 , R 2′ , R 4′ , R 5 , R 5′ , R 6 , R 6′ , and R 9 are each hydrogen.

3. The compound of claim 1 , wherein said substituted tetracycline compound is:

and pharmaceutically acceptable salts thereof.

4. A method for treating a bacterial infection, a viral infection, or a parasitic infection in a subject, comprising administering to said subject an effective amount of a compound of claim 1 , such that said subject is treated.

5. The method of claim 4 , wherein said parasitic infection is malaria.

6. The method of claim 4 , wherein said compound is administered with a pharmaceutically acceptable carrier.

7. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.

8. The composition of claim 7 , wherein said therapeutically effective amount is effective to treat a bacterial infection, a viral infection, or a parasitic infection.

9. A compound of the structure:

or a pharmaceutically acceptable salt thereof.

10. The composition of claim 8 , wherein said parasitic infection is malaria.

Assignments (8)